Related Experiment Videos
Angiogenesis and non-small cell lung cancer
1University Department of Medical Oncology, Leicester Royal Infirmary, UK.
Lung Cancer (Amsterdam, Netherlands)
|February 25, 2000
Summary
Lung cancer, a leading cause of cancer death, shows poor prognosis linked to angiogenesis. Novel therapies targeting this blood vessel growth process offer new treatment possibilities alongside traditional methods.
Area of Science:
- Oncology
- Cancer Biology
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Angiogenesis, the formation of new blood vessels, is increasingly recognized as a critical factor in solid tumor progression.
- Poor prognosis in non-small cell lung cancer (NSCLC) has been associated with tumor angiogenesis.
Purpose of the Study:
- To review the role of angiogenesis in lung cancer.
- To explore novel therapeutic strategies targeting the angiogenic process in lung cancer.
Main Methods:
- Literature review of studies on angiogenesis in lung cancer.
- Analysis of the molecular mechanisms controlling angiogenesis.
- Evaluation of potential anti-angiogenic therapeutic agents.
Main Results:
- Angiogenesis is a complex process involving growth factors, proteases, and adhesion molecules.
- Several novel therapeutic agents targeting angiogenesis are under investigation.
- These include matrix metalloproteinase inhibitors, growth factor antisense RNA, and receptor antagonists.
Conclusions:
- Targeting angiogenesis represents a promising strategy for novel lung cancer therapies.
- Anti-angiogenic agents may be used as monotherapy or in combination with conventional treatments.
- Further research is needed to fully elucidate the potential of anti-angiogenic therapies in lung cancer management.